The April announcement of a biomarker-based diagnosis for Alzheimer's disease by the National Institute of Aging (NIA) and the Alzheimer's Association (AA) came with assurances that their recommendations were meant as a "research framework to investigate the Alzheimer's disease continuum, not as diagnostic criteria and explicitly not intended for clinical use."